Recurrent Respiratory Papillomatosis (RRP) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Recurrent Respiratory Papillomatosis (RRP) Emerging Therapy and TPP Insights

Thelansis's "Recurrent Respiratory Papillomatosis (RRP) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Recurrent Respiratory Papillomatosis (RRP) Overview

Recurrent respiratory papillomatosis (RRP) is a rare, highly morbid viral disease driven by human papillomavirus (HPV) genotypes 6 and 11, characterized by the relentless growth of benign yet obstructive papillomas, primarily in the larynx. The disease manifests in two clinical forms: a more aggressive juvenile-onset variant (JoRRP), typically acquired via vertical transmission, and an adult-onset form (AoRRP) with relatively slower progression but sustained morbidity.

Clinically, RRP leads to progressive airway obstruction, voice impairment, stridor, and recurrent respiratory compromise, often necessitating repeated surgical interventions to maintain airway patency. Due to viral persistence within epithelial cells, the disease follows a chronic relapsing course, with some patients requiring multiple procedures annually.

The traditional standard of care has been repetitive surgical debulking, which, while effective in symptom control, is associated with significant procedural burden and long-term airway damage. However, the treatment paradigm is evolving:

• Widespread prophylactic HPV vaccination is contributing to a declining incidence of juvenile RRP
• Targeted adjuvant therapies, particularly anti-VEGF agents such as bevacizumab, are increasingly used in severe or recalcitrant cases to reduce surgical frequency and preserve airway integrity

Despite these advances, there remains no definitive curative therapy, positioning RRP as a high unmet-need disease with strong momentum toward disease-modifying immunotherapies and therapeutic vaccines.

Key Highlights

• The RRP patient population remains small but steadily growing (1-2% CAGR), with adult-onset cases contributing a larger share (65-70%) compared to juvenile cases.
• HPV 6 and 11 collectively account for 85-90% of cases, reinforcing the strong viral etiology and relevance of vaccine-based strategies.
• Disease burden is driven more by recurrence frequency rather than incidence, with patients requiring multiple surgical interventions annually, especially in JoRRP.
• Current treatment landscape is fragmented and adjunctive-heavy, with:
• High utilization of antivirals and COX inhibitors (60-80% usage in adults)
• Moderate use of immunomodulators and retinoids (25-70%) depending on disease severity
• Adult patients show consistently higher therapy utilization rates vs pediatric, reflecting greater treatment intensity and comorbidity burden.
• Emerging therapies (e.g., therapeutic HPV vaccines and immuno-oncology agents) are expected to shift treatment from procedural to disease-modifying approaches over time.

Market Overview

• The RRP market is expected to grow at a moderate-to-high CAGR (5-7%), driven by:
• Increasing diagnosis and awareness
• Uptake of emerging immunotherapies
• High recurrence-driven treatment demand
• The market remains procedure- and adjunct-therapy driven, with >70-75% contribution from existing supportive and adjunct therapies
• Adult segment dominates revenue (65-70%), supported by higher treatment intensity and greater use of combination/adjuvant therapies
• Emerging therapies are projected to capture 20-30% market share by 2035 & grow at double-digit CAGR

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Precigen, Inc.
• Inovio Pharmaceuticals
• Eisai Inc.
• Merck Sharp & Dohme